Trinity Biotech (NASDAQ:TRIB) Now Covered by Analysts at began coverage on shares of Trinity Biotech (NASDAQ:TRIBFree Report) in a research report sent to investors on Saturday. The brokerage issued a buy rating on the stock.

Trinity Biotech Stock Performance

NASDAQ:TRIB opened at $1.58 on Friday. Trinity Biotech has a 1 year low of $1.49 and a 1 year high of $5.50. The stock has a market cap of $12.04 million, a P/E ratio of -0.50 and a beta of 1.24. The stock has a 50-day simple moving average of $1.90 and a 200-day simple moving average of $2.15.

Trinity Biotech (NASDAQ:TRIBGet Free Report) last announced its quarterly earnings results on Thursday, April 4th. The company reported ($0.68) EPS for the quarter. The business had revenue of $13.43 million for the quarter.

About Trinity Biotech

(Get Free Report)

Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.

Featured Articles

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with's FREE daily email newsletter.